Novavax, Inc. (NASDAQ: NVAX) is having an incredibly strong start to the trading session this morning, and for good reason. The company announced that it will be featured in a coming presentation, exciting investors and sending the stock screaming for the top. Today, we’ll talk about:
- The presentation news;
- what we’re seeing from NVAX stock as a result; and
- what we’ll be watching for ahead.
NVAX Announces Coming Presentation
As mentioned above, Novavax is having a great day in the market today after announcing that it will be presenting soon. The announcement came by way of press release in the after-hours yesterday.
In the release, NVAX said that Gregory M. Glenn, M.D., President of R&D, will share data from its global Phase 3 clinical trial of ResVax. ResVax is the company’s investigational respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine.
In the release, the company said that the oral presentation will take place at the World Vaccine Congress in Washington, D.C.. The event will be held from April 14 through April 17, 2019.
NVAX also said that Louis Fries III, M.D., SVP and CMO, will participate in panel discussions at the World Vaccine Congress on chronic obstructive pulmonary disease.
This is great news as the appearance at the event will not only give the company the ability to showcase data, it opens the doors to networking with leaders in the industry, large investors, and potential partners.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to work in the market is that the news leads to moves. In the case of Novavax, the news proved to be overwhelmingly positive.
After all, the presentation will likely provide further insight into what the company plans to do with the asset following the recent Phase 3 clinical failure. Moreover, it opens the doors to potential partnership opportunities, large investments, and more.
Considering this, it’s not surprising to see that excited investors are pushing the stock on a run for the top. As is just about always the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (9:08), NVAX is trading at $0.57 per share after a gain of $0.02 per share or 3.62% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on NVAX. In particular, we’re interested in following the story surrounding the company’s continued work to bring NanoFlu and ResVax to market. Nonetheless, we’ll continue to keep a close eye on the story and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!